Dermata Therapeutics, Inc. (DRMA) stock
DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.62−0.04 (-6.01%)
Close on Nov 13, 2026Market cap $2.50MP/E –Yield –
Dermata Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Dermata Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.27M, down 72.4% year over year. For fiscal 2025 it was $2.93M, down 64.3% from the year before. The highest annual figure on record is $8.20M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.93M | -64.3% |
| FY2024 | Dec 31, 2024 | $8.20M | +101.6% |
| FY2023 | Dec 31, 2023 | $4.07M | -28.0% |
| FY2022 | Dec 31, 2022 | $5.65M | +63.4% |
| FY2021 | Dec 31, 2021 | $3.46M | +115.2% |
| FY2020 | Dec 31, 2020 | $1.61M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $143.29K | -71.6% |
| Q2 FY2026 | Jun 30, 2026 | $212.56K | -65.6% |
| Q1 FY2026 | Mar 31, 2026 | $383.72K | -70.0% |
| Q4 FY2025 | Dec 31, 2025 | $526.62K | -76.0% |
| Q3 FY2025 | Sep 30, 2025 | $504.39K | -79.0% |
| Q2 FY2025 | Jun 30, 2025 | $617.84K | -69.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.28M | -20.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.19M | +93.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.40M | +165.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.01M | +139.5% |
| Q1 FY2024 | Mar 31, 2024 | $1.60M | +34.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.14M | +27.6% |
| Q3 FY2023 | Sep 30, 2023 | $902.98K | -41.9% |
| Q2 FY2023 | Jun 30, 2023 | $838.93K | -48.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.19M | -25.3% |
| Q4 FY2022 | Dec 31, 2022 | $889.36K | -20.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.55M | +94.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.61M | +85.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.60M | +134.5% |
| Q4 FY2021 | Dec 31, 2021 | $1.11M | +872.7% |
| Q3 FY2021 | Sep 30, 2021 | $799.78K | +563.9% |
| Q2 FY2021 | Jun 30, 2021 | $867.20K | +110.5% |
| Q1 FY2021 | Mar 31, 2021 | $680.59K | – |
| Q4 FY2020 | Dec 31, 2020 | $114.30K | – |
| Q3 FY2020 | Sep 30, 2020 | $120.47K | – |
| Q2 FY2020 | Jun 30, 2020 | $411.95K | – |
See a number that looks wrong?